uniQure (NASDAQ:QURE – Get Free Report) had its price target cut by stock analysts at HC Wainwright from $80.00 to $65.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright‘s target price indicates a potential upside of 221.30% from the stock’s previous close.
A number of other brokerages also recently issued reports on QURE. Barclays downgraded shares of uniQure from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $60.00 to $28.00 in a report on Monday, October 5th. William Blair raised shares of uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. UBS Group started coverage on shares of uniQure in a report on Thursday, October 15th. They issued a “buy” rating and a $48.00 target price for the company. Finally, Stifel Nicolaus set a $71.00 target price on shares of uniQure in a report on Wednesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.58.
Get Our Latest Stock Report on QURE
uniQure Trading Down 0.3%
uniQure (NASDAQ:QURE – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.88) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.04. The company had revenue of $5.20 million during the quarter, compared to the consensus estimate of $6.17 million. uniQure had a negative return on equity of 96.34% and a negative net margin of 1,154.84%. On average, sell-side analysts anticipate that uniQure will post -3.83 earnings per share for the current fiscal year.
Institutional Investors Weigh In On uniQure
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Algert Global LLC boosted its position in uniQure by 55.0% in the 3rd quarter. Algert Global LLC now owns 35,630 shares of the biotechnology company’s stock valued at $861,000 after buying an additional 12,650 shares during the last quarter. Flax Pond Capital LLC grew its stake in shares of uniQure by 4.7% during the third quarter. Flax Pond Capital LLC now owns 164,157 shares of the biotechnology company’s stock valued at $3,966,000 after acquiring an additional 7,431 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of uniQure during the third quarter valued at about $2,626,000. Jump Financial LLC purchased a new stake in shares of uniQure during the third quarter worth about $235,000. Finally, Marshall Wace LLP increased its position in shares of uniQure by 89.1% during the third quarter. Marshall Wace LLP now owns 576,162 shares of the biotechnology company’s stock worth $13,920,000 after acquiring an additional 271,460 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.
About uniQure
uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.
Further Reading
- Five stocks we like better than uniQure
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
